Paxlovid speeds COVID-19 recovery but does not reduce hospital admissions Across two trials, more than 4,000 patients were randomised to receive usual care or Paxlovid (nirmatrelvir and ritonavir; Pfizer) within three or four days of symptom onset.…
Manufacturer to warn of fatal adverse reactions from blood-clotting drug and anaesthetic mix-ups A letter from Pfizer cautions healthcare professionals to use extreme caution when storing, handling and administrating IV formulations of tranexamic acid.…
Pharmacists ‘perfectly placed’ to deliver nationally commissioned weight-loss service, MPs told Attendees of the Health and Social Care Committee session emphasised the importance of “wrap-around care” alongside prescribing GLP-1 medicines.…
Regulators set out support for in-orbit pharmaceutical manufacturing In a joint statement, UK regulators said that the production of materials and products in space have the potential to offer higher quality medicines compared with those made on Earth.…
‘Two double decker buses’ worth of illegal erectile dysfunction drugs seized by MHRA The Medicines and Healthcare products Regulatory Agency seized over 4.4 million doses of unlicensed erectile dysfunction medicines in 2025 alone.…
Nearly 400 ‘dormant’ medicines targeted to be revived by government, industry and NHS scheme Medicines UK said that the collaborative project would focus on 'dormant' medicines that represent a serious risk to supply resilience and could result in medicines shortages.…
Everything you need to know about GLP-1s for weight loss From semaglutide to tirzepatide, this article collates the latest information on pharmacological weight-loss treatments, including evidence and best practice for their use.…
Class 1 recall issued for quetiapine oral suspension A national patient safety alert said that pharmacy teams must immediately stop supplying affected products, as well as quarantine and return any remaining stock.…
Health news round-up: NICE approvals, surveillance data and GLP-1 warnings A weekly summary of important developments in pharmacy and health news that you may have missed.…
PJ view: Access to rare disease treatment should not be a rarity Policymakers and healthcare leaders must persevere with long overdue changes to improve access to treatments for rare diseases.…
